We will test the hypothesis that IL-23 is a new and important player and potential target in systemic sclerosis (SSc). We hypothesize that IL-23 signaling plays a critical pathogenic role in SSc by driving fibrosis, vasculopathy and/or inflammation. Therefore, we predict that blocking IL-23 will prevent and promote resolution of tissue inflammation and fibrosis in preclinical disease models of scleroderma in the mouse. Antibody blockade of IL-23 might therefore be potential novel treatment in SSc patients demonstrating evidence of activated IL-23 signaling in lesional skin.
|Effective start/end date||7/11/19 → 7/11/22|
- Sun Pharma Global FZE (IS00011264)